Close

Jump to:

  • Navigation
  • Content
  • Footer
Nordic microbes hero image

Nordic microbes

Follow

We change how we grow food in Europe using microbes

101%
 - 
Funded 20 Dec 2025
£4,350,024 target
£4,412,880 from 166 investors
More
Less

Business overview

Location Odense C, Denmark
Social media
Website www.nordicmicrobes.com
Sectors Food & Beverage Non-Digital B2B
Company number 42559997
Incorporation date 23 Jul 2021
More
Less

Investment summary

Type Equity
Valuation (pre-money) £25.8M
Equity offered 14.62%
Share price £54
UK tax relief N/A
More
Less

Business highlights

  • Patent-pending biosolutions
  • Used by hundreds of farms
  • Sales in Denmark, Sweden and the UK
  • Fast-growing billion-euro target market
More
Less

Key features

  • Secondary Market
  • Nominee investment min. £54.00 +
  • Pitch
  • Key Information
  • Team
  • Updates
  • Investors 166
  • Discussion
  • Documents

Pitch

About the Campaign

Our commercially available biosolutions are an effective alternative to the chemical inputs used in modern farming. We aim to reduce chemicals in our environment and food, and enable farmers to stay productive during tough times.

Join Nordic microbes on our critical mission:

Market Opportunity

Without new solutions, food production will be threatened, and Europe may fail to meet its growing food demand.

Our biosolutions give farmers a fighting chance against the problems ahead. We use naturally occurring microbes to address this €10B agrochemical market.

Traction & Key Accomplishments

Use of Funds

You can help us secure industry partnerships and complete regulatory testing of our biofungicide. With you aboard, we can expand international sales, production and further testing of our biostimulants. We aim to open new regions to increase market share and impact on our environment and food.

Key Information

Key information investment sheet

Key Investment Information Sheet is available by downloading the following documents:

  • Key Investment Information Sheet [Danish]
  • Key Investment Information Sheet [German]
  • Key Investment Information Sheet [English]
  • Key Investment Information Sheet [Spanish]
  • Key Investment Information Sheet [French]
  • Key Investment Information Sheet [Italian]
  • Key Investment Information Sheet [Dutch]
  • Key Investment Information Sheet [Portuguese]
  • Key Investment Information Sheet [Swedish]

License Agreement

Nordic Microbes’ core technology and microbial strains are secured through an exclusive, worldwide license agreement with the University of Southern Denmark and The University of Western Australia.

Under the agreement, the company pays tiered royalties on sales, which start at 3% for early products and services and decrease over time.

Once the company raises 25 million DKK in equity investment, it has the right to acquire full ownership of the patents for a one-time payment of 200,000 DKK (€26.8k). The company also has a separate option to completely buy out all future royalty obligations for a fixed fee, starting at 4 million DKK (€535k).

Founders Interest

The founder and CEO, Morten Østergaard Andersen, is a shareholder in Ossiform Ltd, a company he co-founded in 2017 and currently has no formal commitments.

Currency exchange rate

Some direct investments in the round from investors outside of Republic Europe have been paid in Danish Krones (DKK). This amount has been reflected in the campaign at an agreed Exchange Rate (set on 07/11/25) of 1: 0.12 DKK to GBP.

Investments on Republic Europe are made in GBP.

Open an account to get access to the team members of Nordic microbes

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for Nordic microbes has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 11 November 2025 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £25,761,240

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Republic Europe.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Republic Europe

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Republic Europe campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Nominee investment

This shows if you are able to choose, when making an investment, that you be represented by, and your shareholding be managed by, the Nominee investment.

Find out more

Custodian

If you invest in this Campaign, Republic Europe will act as Custodian rather than provide our standard nominee service. This is due to the fact that the business is not directly involved in the share sale and Republic Europe will not benefit from any rights under a shareholder agreement. As a result, Republic Europe will handle administrative tasks as we do normally, but you will not have information or voting rights, updates from the business, preemption on future fundraising, or ongoing support about business trading activity.

Learn more about Custodian here

Secondary market

This shows if the business has opted-in or opted-out of allowing its shares to be bought and sold on the secondary market.

Find out more

Direct investment

If available, this is an option to invest and hold shares 'directly' in the company (rather than via the Nominee investment). This option is only available to those investing over the threshold amount, which is determined by the fundraising company.

If you choose to hold your shares directly, you will be responsible for any contractual or administrative arrangements with the company you are investing in.

Find out more

Payment options

We are not able to accept card payments for investments into this sector. You can pay for your investment by creating a bank transfer, using funds in your investment account or create a Pay by Bank payment. Your investment will only be completed once the funds have reached our account.

Business Involvement

This Campaign offers shares for sale in business that is not directly involved in this Campaign or the sale. As a result, the Campaign and post-investment experience, including investor rights, will differ from a business-led campaign on Republic Europe. Most notably, the business will not engage with investors in the discussion forums both during and after the sale or provide any updates to investors.

Learn more here

Payment options

We are not able to accept Pay by Bank payments for investments into this sector. You can pay for your investment with a card payment, by creating a bank transfer or by using funds in your investment account. Your investment will only be completed once the funds have reached our account.

Drawdowns

This campaign offers the ability to pay for an investment by drawdowns.

Security Token

A security token is a digital asset that represents ownership or other rights. It is a digital form of traditional investments. In the future, you may be able to trade your investment through compatible exchanges.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Republic Europe.

ContinueCancel